Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tina Sarbajna"'
Autor:
Susan Galbraith, Barry Crean, Gyorgy Zorenyi, Caroline Germa, Gaia Schiavon, Amaya Gasco Hernandez, Benjamin G. Challis, Eden Harrison, James Hadfield, Tina Sarbajna, Zoltan Szucs, Marianne Ashford, Farzana Walcott, Alula R. Yohannes, Michele Moschetta, Andrew R. Reynolds
Despite some notable successes, there are still relatively few agents approved for cancer prevention. Here we review progress thus far in the development of medicines for cancer prevention, and we outline some key concepts that could further enable o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497147f971b38aaa0976b8d04d58dd9d
https://doi.org/10.1158/2159-8290.c.6602824.v1
https://doi.org/10.1158/2159-8290.c.6602824.v1
Autor:
Susan Galbraith, Barry Crean, Gyorgy Zorenyi, Caroline Germa, Gaia Schiavon, Amaya Gasco Hernandez, Benjamin G. Challis, Eden Harrison, James Hadfield, Tina Sarbajna, Zoltan Szucs, Marianne Ashford, Farzana Walcott, Alula R. Yohannes, Michele Moschetta, Andrew R. Reynolds
Tables that provide additional information to support the main article
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0655685c8a1eeb07fa541d987352f87
https://doi.org/10.1158/2159-8290.22644241
https://doi.org/10.1158/2159-8290.22644241
Autor:
Sukhvinder Johal, Miguel Miranda, Tina Sarbajna, Xiaojin Shi, Alastair Greystoke, Melissa Johnson
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fb6b6a4254e41b2966ca162339d601b
https://doi.org/10.1136/jitc-2022-sitc2022.0581
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Autor:
Peter Elroy, W. Dunlop, Ignacio Diaz Perez, Alastair Greystoke, Tina Sarbajna, Marjolijn van Keep, Mario Ouwens, Yiduo Zhang
Publikováno v:
PharmacoEconomics - open. 6(2)
In the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe11124e62815b8e7f0e833a25f03e43
https://pubmed.ncbi.nlm.nih.gov/34532842
https://pubmed.ncbi.nlm.nih.gov/34532842